Sponsor Directory

Eli Lilly and Company clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1963

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Diabetes Mellitus, Type 2
Interventions: Orforglipron, Dulaglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 17
States / cities: Sacramento, California • San Diego, California • Stamford, Connecticut + 14 more

Conditions: Neoplasms
Interventions: Encorafenib, Cetuximab, Oxaliplatin, Irinotecan, Leucovorin, 5-FU, Capecitabine, Bevacizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 63
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 38 more

Conditions: Asthma
Interventions: Brenipatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 18
States / cities: Tempe, Arizona • Newport Beach, California • Northridge, California + 14 more

Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Interventions: Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel; Drug
Lead sponsor: ALX Oncology Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Anaheim, California • Los Angeles, California • Nashville, Tennessee + 2 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Brenipatide, Placebo, Standard of Care; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Newport Beach, California • San Diego, California + 15 more

Conditions: Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
Interventions: LY4405094, Placebo, Florbetapir F18, Florbetaben F 18; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Anaheim, California • Irvine, California • Los Alamitos, California + 10 more

Conditions: Irritable Bowel Syndrome, Constipation
Interventions: LY3537031, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Mesa, Arizona • Anaheim, California • Lancaster, California + 11 more

Conditions: Healthy
Interventions: LY4515100 via SAD, LY4515100 via MAD, LY4515100, Itraconazole, Caffeine, Digoxin, Iohexol, Metformin, Rosuvastatin, Placebo, Midazolam, Levonorgestrel, Ethinyl Estradiol; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal
Interventions: Orforglipron, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 80
States / cities: Anniston, Alabama • Birmingham, Alabama • Pelham, Alabama + 73 more

Conditions: Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Interventions: LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo, LY4065967 ISA; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 62
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 52 more

Conditions: Breast Neoplasms, Neoplasm Metastasis
Interventions: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib, Anastrozole, Letrozole, Exemestane, Fulvestrant; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 132
States / cities: Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 112 more

Conditions: Alzheimer Disease
Interventions: LY3439539; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 5 more

About this Eli Lilly and Company sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Eli Lilly and Company is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Eli Lilly and Company trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Eli Lilly and Company clinical trials

Filter and sort this sponsor

Live official records

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

A Study of LY4515100 in Healthy Participants

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

A Study of LY3439539 in Participants With Alzheimer's Disease

About this Eli Lilly and Company sponsor directory page